KCM
MXCT icon

Kennedy Capital Management’s MaxCyte MXCT Stock Holding History

Kennedy Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,107,392
Closed -$3.33M – 573
2025
Q3 		$3.33M Buy
+2,107,392
New +$3.66M 0.07% 364

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's MXCT Position: Q4 2025 in Review

Kennedy Capital Management sold out of MaxCyte (MXCT) in Q4 2025, closing a stake of 2,107,392 shares — an estimated $3.33M sold.

Kennedy Capital Management first reported a position in MXCT in Q3 2025 and held it in 1 quarter. The position peaked at $3.33M in Q3 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q4 2025.

  • Kennedy Capital Management reported no remaining MaxCyte position as of Q4 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 2,107,392 MaxCyte shares in Q4 2025, an estimated $3.33M.
  • Kennedy Capital Management first reported a position in MaxCyte in Q3 2025 and held it in 1 quarter.
  • Kennedy Capital Management's MaxCyte position peaked at $3.33M in Q3 2025.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q4 2025.

Based on Kennedy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.